{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T21:00:33Z","timestamp":1784926833527,"version":"3.55.0"},"reference-count":129,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Oncogenic gene fusions define a clinically important subset of non\u2013small cell lung carcinoma (NSCLC) for which targeted therapies have transformed outcomes. Over the past 15 years, successive generations of tyrosine kinase inhibitors (and more recently, monoclonal antibodies) have demonstrated substantial improvements in response rates, progression-free survival, and central nervous system control across multiple fusion-defined populations. This review consolidates current evidence for FDA-approved therapies targeting ALK, ROS1, RET, NTRK, and NRG1 fusions in lung cancer, highlighting mechanisms of action, pivotal clinical trials, resistance patterns, and toxicity profiles. We also discuss advances in molecular diagnostics (including the growing role of RNA-based sequencing) and emerging strategies in the adjuvant and perioperative settings. Finally, we outline ongoing clinical trials and future directions aimed at overcoming resistance and expanding precision oncology approaches for patients with rare fusion-driven lung cancers.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000837","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T20:00:30Z","timestamp":1784923230000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Targeting Oncogenic Gene Fusions in Lung Cancer"],"prefix":"10.1097","volume":"32","author":[{"given":"Yunan","family":"Nie","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Section of Medical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick H.","family":"Wilson","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section of Medical Oncology"},{"name":"Department of Genetics"},{"name":"Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7]]},"reference":[{"key":"R1-20260724","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R3-20260724","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1158\/1078-0432.CCR-11-2511","article-title":"Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis","volume":"18","author":"Zhang","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R4-20260724","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/cncr.29812","article-title":"Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: results from the Lung Cancer Mutation Consortium","volume":"122","author":"Steuer","year":"2016","journal-title":"Cancer"},{"key":"R5-20260724","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/oncolo\/oyac035","article-title":"Targeted next-generation sequencing reveals exceptionally high rates of molecular driver mutations in never-smokers with lung adenocarcinoma","volume":"27","author":"Mack","year":"2022","journal-title":"Oncologist"},{"key":"R6-20260724","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.cell.2012.08.024","article-title":"Genomic landscape of non-small cell lung cancer in smokers and never-smokers","volume":"150","author":"Govindan","year":"2012","journal-title":"Cell"},{"key":"R7-20260724","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(16)00004-0","article-title":"Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)","volume":"387","author":"Barlesi","year":"2016","journal-title":"Lancet"},{"key":"R8-20260724","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","year":"2014","journal-title":"Nature"},{"key":"R9-20260724","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1097\/JTO.0000000000000481","article-title":"Updated frequency of EGFR and KRAS mutations in nonsmall-cell lung cancer in Latin America: the Latin-American Consortium for the Investigation of Lung Cancer (CLICaP)","volume":"10","author":"Arrieta","year":"2015","journal-title":"J Thorac Oncol"},{"key":"R10-20260724","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3390\/cancers17050730","article-title":"Distribution of EGFR and KRAS mutations in patients with surgically resected non-small cell lung cancer from southern Italy: real-life data from a single institution and literature review","volume":"17","author":"Piazzolla","year":"2025","journal-title":"Cancers"},{"key":"R11-20260724","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.3390\/cancers17223673","article-title":"Comprehensive molecular diagnostic tests in non-small cell lung cancer: frequency of ALK, ROS1, RET, and other gene fusions\/rearrangements in a Romanian cohort","volume":"17","author":"Cohn (Vizitiu)","year":"2025","journal-title":"Cancers"},{"key":"R12-20260724","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1097\/JTO.0000000000000620","article-title":"Profiling of oncogenic driver events in lung adenocarcinoma revealed MET mutation as independent prognostic factor","volume":"10","author":"Yeung","year":"2015","journal-title":"J Thorac Oncol"},{"key":"R13-20260724","doi-asserted-by":"crossref","first-page":"13257","DOI":"10.1073\/pnas.0405490101","article-title":"Finding fusion genes resulting from chromosome rearrangement by analyzing the expressed sequence databases","volume":"101","author":"Hahn","year":"2004","journal-title":"Proc Natl Acad Sci"},{"key":"R15-20260724","doi-asserted-by":"crossref","first-page":"5581","DOI":"10.1158\/1078-0432.CCR-10-0851","article-title":"Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment","volume":"16","author":"Camidge","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R16-20260724","doi-asserted-by":"crossref","first-page":"1225646","DOI":"10.3389\/fonc.2023.1225646","article-title":"Comprehensive NGS profiling to enable detection of ALK gene rearrangements and MET amplifications in non-small cell lung cancer","volume":"13","author":"Clav\u00e9","year":"2023","journal-title":"Front Oncol"},{"key":"R17-20260724","doi-asserted-by":"crossref","first-page":"e2442970","DOI":"10.1001\/jamanetworkopen.2024.42970","article-title":"Actionable structural variant detection via RNA-NGS and DNA-NGS in patients with advanced non\u2013small cell lung cancer","volume":"7","author":"Owen","year":"2024","journal-title":"JAMA Netw Open"},{"key":"R18-20260724","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1200\/JCO.21.02767","article-title":"Somatic genomic testing in patients with metastatic or advanced cancer: ASCO provisional clinical opinion","volume":"40","author":"Chakravarty","year":"2022","journal-title":"J Clin Oncol"},{"key":"R19-20260724","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1158\/1078-0432.CCR-19-0225","article-title":"High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden","volume":"25","author":"Benayed","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R20-20260724","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.21037\/tlcr-2025-702","article-title":"Characterization of RET fusions via integrated DNA and RNA sequencing in early-stage non-small cell lung cancer: a retrospective study","volume":"14","author":"Ding","year":"2025","journal-title":"Transl Lung Cancer Res"},{"key":"R21-20260724","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jmoldx.2025.02.007","article-title":"Comparison of targeted RNA-sequencing platforms for oncogenic fusion detection in non\u2013small-cell lung cancer","volume":"27","author":"Dillard","year":"2025","journal-title":"J Mol Diagn"},{"key":"R23-20260724","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in resected ALK-positive non\u2013small-cell lung cancer","volume":"390","author":"Wu","year":"2024","journal-title":"N Engl J Med"},{"key":"R24-20260724","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.2217\/fon-2022-0656","article-title":"LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer","volume":"18","author":"Tsuboi","year":"2022","journal-title":"Future Oncol"},{"key":"R25-20260724","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jtho.2018.09.001","article-title":"Increased hepatotoxicity associated with sequential immune checkpoint inhibitor and crizotinib therapy in patients with non\u2013small cell lung cancer","volume":"14","author":"Lin","year":"2019","journal-title":"J Thorac Oncol"},{"key":"R26-20260724","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1200\/EDBK_280795","article-title":"Checkpoint blockade in lung cancer with driver mutation: choose the road wisely","volume":"40","author":"Calles","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R27-20260724","doi-asserted-by":"crossref","first-page":"e002891","DOI":"10.1136\/jitc-2021-002891","article-title":"Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer","volume":"9","author":"Negrao","year":"2021","journal-title":"J Immunother Cancer"},{"key":"R28-20260724","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(18)30144-X","article-title":"Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study","volume":"19","author":"Garassino","year":"2018","journal-title":"Lancet Oncol"},{"key":"R29-20260724","doi-asserted-by":"crossref","first-page":"322","DOI":"10.21037\/tlcr-22-883","article-title":"Narrative review: immunotherapy in anaplastic lymphoma kinase (ALK)+ lung cancer-current status and future directions","volume":"12","author":"Schenk","year":"2023","journal-title":"Transl Lung Cancer Res"},{"key":"R30-20260724","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41392-022-01168-8","article-title":"Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective","volume":"7","author":"Yang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"R31-20260724","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.lungcan.2017.11.001","article-title":"Clinical characteristics and sequence complexity of anaplastic lymphoma kinase gene fusions in Chinese lung cancer patients","volume":"114","author":"Tian","year":"2017","journal-title":"Lung Cancer"},{"key":"R32-20260724","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00018-015-2117-6","article-title":"Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs","volume":"73","author":"Bayliss","year":"2016","journal-title":"Cell Mol Life Sci"},{"issue":"suppl 3","key":"R33-20260724","doi-asserted-by":"crossref","first-page":"iii4","DOI":"10.1093\/annonc\/mdw301","article-title":"The role of the ALK receptor in cancer biology","volume":"27","author":"Hallberg","year":"2016","journal-title":"Ann Oncol"},{"key":"R34-20260724","first-page":"100015","article-title":"Catalog of 5'fusion partners in ALK-positive NSCLC circa 2020","volume":"1","author":"Ou","year":"2020","journal-title":"JTO Clin Res Rep"},{"key":"R35-20260724","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2015.65.8732","article-title":"Differential crizotinib response duration among ALK fusion variants in ALK-positive non\u2013small-cell lung cancer","volume":"34","author":"Yoshida","year":"2016","journal-title":"J Clin Oncol"},{"key":"R36-20260724","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1200\/JCO.2017.76.2294","article-title":"Impact of EML4-ALK variant on resistance mechanisms and clinical outcomes in ALK-positive lung cancer","volume":"36","author":"Lin","year":"2018","journal-title":"J Clin Oncol"},{"key":"R37-20260724","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.jtho.2024.07.009","article-title":"Impact of EML4-ALK variants and co-occurring TP53 mutations on duration of first-line ALK tyrosine kinase inhibitor treatment and overall survival in ALK fusion-positive NSCLC: real-world outcomes from the GuardantINFORM database","volume":"19","author":"Parikh","year":"2024","journal-title":"J Thorac Oncol"},{"key":"R38-20260724","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1158\/2159-8290.CD-16-1123","article-title":"Targeting ALK: precision medicine takes on drug resistance","volume":"7","author":"Lin","year":"2017","journal-title":"Cancer Discov"},{"key":"R39-20260724","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med"},{"key":"R40-20260724","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1200\/JCO.2017.77.4794","article-title":"Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non\u2013small-cell lung cancer","volume":"36","author":"Solomon","year":"2018","journal-title":"J Clin Oncol"},{"key":"R41-20260724","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N Engl J Med"},{"key":"R42-20260724","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non\u2013small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"R43-20260724","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","volume":"31","author":"Mok","year":"2020","journal-title":"Ann Oncol"},{"key":"R44-20260724","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.annonc.2025.09.018","article-title":"Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study","volume":"37","author":"Peters","year":"2026","journal-title":"Ann Oncol"},{"key":"R45-20260724","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non\u2013small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N Engl J Med"},{"key":"R46-20260724","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","article-title":"Brigatinib versus crizotinib in ALK inhibitor\u2013naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial","volume":"16","author":"Camidge","year":"2021","journal-title":"J Thorac Oncol"},{"key":"R47-20260724","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jamaoncol.2021.3523","article-title":"Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase\u2212positive non\u2013small cell lung cancer: a randomized clinical trial","volume":"7","author":"Horn","year":"2021","journal-title":"JAMA Oncol"},{"key":"R48-20260724","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","volume":"389","author":"Soria","year":"2017","journal-title":"Lancet"},{"key":"R49-20260724","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S1470-2045(17)30339-X","article-title":"Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol"},{"key":"R50-20260724","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J Med"},{"key":"R51-20260724","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S2213-2600(22)00437-4","article-title":"Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir Med"},{"key":"R52-20260724","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib versus crizotinib in patients with advanced ALK-positive non\u2013small cell lung cancer: 5-year outcomes from the phase III CROWN study","volume":"42","author":"Solomon","year":"2024","journal-title":"J Clin Oncol"},{"key":"R53-20260724","doi-asserted-by":"crossref","first-page":"e443","DOI":"10.1200\/JCO.2010.34.1313","article-title":"CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib","volume":"29","author":"Costa","year":"2011","journal-title":"J Clin Oncol"},{"key":"R54-20260724","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2169\/internalmedicine.1072-18","article-title":"A low crizotinib concentration in the cerebrospinal fluid causes ineffective treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer with carcinomatous meningitis","volume":"58","author":"Okimoto","year":"2019","journal-title":"Intern Med"},{"key":"R55-20260724","doi-asserted-by":"crossref","first-page":"bcr-2013-200867","DOI":"10.1136\/bcr-2013-200867","article-title":"Long-lasting response to crizotinib in brain metastases due to EML4-ALK-rearranged non-small-cell lung cancer","volume":"2013","author":"Kinoshita","year":"2013","journal-title":"BMJ Case Rep"},{"key":"R56-20260724","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.jtho.2018.07.001","article-title":"The incidence of brain metastases in stage IV ROS1-rearranged non\u2013small cell lung cancer and rate of central nervous system progression on crizotinib","volume":"13","author":"Patil","year":"2018","journal-title":"J Thorac Oncol"},{"key":"R57-20260724","first-page":"100909","article-title":"Crizotinib in patients with ROS1-positive non-small-cell lung cancer with or without brain metastases: post-hoc analysis of phase II METROS trial","volume":"6","author":"Landi","year":"2025","journal-title":"JTO Clin Res Rep"},{"key":"R58-20260724","doi-asserted-by":"crossref","first-page":"101121","DOI":"10.1016\/j.tranon.2021.101121","article-title":"Efficacy of lorlatinib in lung carcinomas carrying distinct ALK translocation variants: the results of a single-center study","volume":"14","author":"Orlov","year":"2021","journal-title":"Transl Oncol"},{"key":"R59-20260724","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.cllc.2024.08.003","article-title":"Comparative efficacy and safety of lorlatinib versus alectinib and lorlatinib versus brigatinib for ALK-positive advanced\/metastatic NSCLC: matching-adjusted indirect comparisons","volume":"25","author":"Garcia","year":"2024","journal-title":"Clin Lung Cancer"},{"key":"R60-20260724","doi-asserted-by":"crossref","first-page":"oyaf287","DOI":"10.1093\/oncolo\/oyaf287","article-title":"Kinetics and management of adverse events associated with lorlatinib after 5 years of follow-up in the CROWN study","volume":"30","author":"Liu","year":"2025","journal-title":"Oncologist"},{"key":"R61-20260724","doi-asserted-by":"crossref","first-page":"107954","DOI":"10.1016\/j.lungcan.2024.107954","article-title":"Association between lorlatinib blood concentration and adverse events and clinical impact of dose modification","volume":"196","author":"Igawa","year":"2024","journal-title":"Lung Cancer"},{"key":"R62-20260724","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jtho.2019.10.015","article-title":"ALK mutation status before and after alectinib treatment in locally advanced or metastatic ALK-positive NSCLC: pooled analysis of two prospective trials","volume":"15","author":"No\u00e9","year":"2020","journal-title":"J Thorac Oncol"},{"key":"R63-20260724","doi-asserted-by":"crossref","first-page":"120ra17","DOI":"10.1126\/scitranslmed.3003316","article-title":"Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers","volume":"4","author":"Katayama","year":"2012","journal-title":"Sci Transl Med"},{"key":"R64-20260724","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/JTO.0b013e318241daab","article-title":"Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation","volume":"7","author":"Costa","year":"2012","journal-title":"J Thorac Oncol"},{"key":"R65-20260724","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.1158\/1078-0432.CCR-16-1415","article-title":"Personalized medicine tackles clinical resistance: alectinib in ALK-Positive non\u2013small cell lung cancer progressing on first-generation ALK inhibitor","volume":"22","author":"Skoulidis","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R66-20260724","doi-asserted-by":"crossref","first-page":"105574","DOI":"10.1016\/j.esmoop.2025.105574","article-title":"Plasma cfDNA analysis of alectinib resistance-related gene alterations in the J-ALEX study","volume":"10","author":"Sakaguchi","year":"2025","journal-title":"ESMO Open"},{"key":"R67-20260724","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","article-title":"Molecular mechanisms of resistance to first-and second-generation ALK inhibitors in ALK-rearranged lung cancer","volume":"6","author":"Gainor","year":"2016","journal-title":"Cancer Discov"},{"key":"R68-20260724","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/s43018-022-00399-6","article-title":"Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer","volume":"3","author":"Shiba-Ishii","year":"2022","journal-title":"Nat Cancer"},{"key":"R69-20260724","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/bjc.2011.586","article-title":"Combined effect of ALK and MEK inhibitors in EML4-ALK-positive non-small-cell lung cancer cells","volume":"106","author":"Tanizaki","year":"2012","journal-title":"Br J Cancer"},{"key":"R70-20260724","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1038\/bjc.2014.36","article-title":"RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis","volume":"110","author":"Tsuta","year":"2014","journal-title":"Br J Cancer"},{"key":"R71-20260724","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1200\/JCO.2012.44.1477","article-title":"RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer","volume":"30","author":"Wang","year":"2012","journal-title":"J Clin Oncol"},{"key":"R72-20260724","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jtho.2017.10.021","article-title":"Clinical and translational implications of RET rearrangements in non\u2013small cell lung cancer","volume":"13","author":"Ferrara","year":"2018","journal-title":"J Thorac Oncol"},{"key":"R73-20260724","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.jtho.2018.07.004","article-title":"Frequency of brain metastases and multikinase inhibitor outcomes in patients with RET\u2013rearranged lung cancers","volume":"13","author":"Drilon","year":"2018","journal-title":"J Thorac Oncol"},{"key":"R74-20260724","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2005653","article-title":"Efficacy of selpercatinib in RET fusion\u2013positive non\u2013small-cell lung cancer","volume":"383","author":"Drilon","year":"2020","journal-title":"N Engl J Med"},{"key":"R75-20260724","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1200\/JCO-24-02076","article-title":"Selpercatinib in RET fusion\u2013positive non\u2013small cell lung cancer: final safety and efficacy, including overall survival, from the LIBRETTO-001 phase I\/II trial","volume":"43","author":"Gautschi","year":"2025","journal-title":"J Clin Oncol"},{"key":"R76-20260724","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1470-2045(21)00247-3","article-title":"Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1\/2 study","volume":"22","author":"Gainor","year":"2021","journal-title":"Lancet Oncol"},{"key":"R77-20260724","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa2309457","article-title":"First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion\u2013positive NSCLC","volume":"389","author":"Zhou","year":"2023","journal-title":"N Engl J Med"},{"key":"R78-20260724","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.annonc.2022.08.002","article-title":"Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial","volume":"33","author":"Griesinger","year":"2022","journal-title":"Ann Oncol"},{"key":"R79-20260724","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S1470-2045(16)30562-9","article-title":"Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial","volume":"17","author":"Drilon","year":"2016","journal-title":"Lancet Oncol"},{"key":"R80-20260724","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S2213-2600(16)30322-8","article-title":"Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial","volume":"5","author":"Yoh","year":"2017","journal-title":"Lancet Respir Med"},{"key":"R81-20260724","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.lungcan.2021.03.002","article-title":"Final survival results for the LURET phase II study of vandetanib in previously treated patients with RET-rearranged advanced non-small cell lung cancer","volume":"155","author":"Yoh","year":"2021","journal-title":"Lung Cancer"},{"key":"R82-20260724","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1080\/14796694.2025.2508132","article-title":"Matching-adjusted indirect comparison of selpercatinib and pralsetinib in RET fusion-positive non-small cell lung cancer","volume":"21","author":"Hochmair","year":"2025","journal-title":"Future Oncol"},{"issue":"suppl","key":"R83-20260724","doi-asserted-by":"crossref","first-page":"8644","DOI":"10.1200\/JCO.2025.43.16_suppl.8644","article-title":"Efficacy and safety of pralsetinib in patients with advanced RET -fusion-positive NSCLC: final data from the phase 1\/2 ARROW study","volume":"43","author":"Lopes","year":"2025","journal-title":"JCO"},{"key":"R84-20260724","doi-asserted-by":"crossref","first-page":"1424980","DOI":"10.3389\/fphar.2024.1424980","article-title":"Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system","volume":"15","author":"Jie","year":"2024","journal-title":"Front Pharmacol"},{"key":"R85-20260724","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.lungcan.2019.09.011","article-title":"A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma","volume":"138","author":"Hida","year":"2019","journal-title":"Lung Cancer"},{"key":"R86-20260724","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1093\/annonc\/mdw163","article-title":"Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers","volume":"27","author":"Drilon","year":"2016","journal-title":"Ann Oncol"},{"key":"R87-20260724","doi-asserted-by":"crossref","first-page":"e240224","DOI":"10.1530\/ERC-24-0224","article-title":"Mechanisms of resistance to RET-directed therapies","volume":"32","author":"Clifton-Bligh","year":"2025","journal-title":"Endocr Relat Cancer"},{"key":"R88-20260724","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41698-024-00563-4","article-title":"Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer","volume":"8","author":"Subbiah","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"R89-20260724","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1158\/1078-0432.CCR-12-2851","article-title":"Molecular pathways: ROS1 fusion proteins in cancer","volume":"19","author":"Davies","year":"2013","journal-title":"Clin Cancer Res"},{"key":"R90-20260724","doi-asserted-by":"crossref","first-page":"116091","DOI":"10.1016\/j.ejca.2025.116091","article-title":"Molecular and clinical characteristics of ROS1 fusion variants in ROS1-rearranged cancers: a defined role of fusion partners and breakpoints of ROS1","volume":"231","author":"Jeong","year":"2025","journal-title":"Eur J Cancer"},{"key":"R91-20260724","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1097\/JTO.0000000000000118","article-title":"Coexistence of three variants involving two different fusion partners of ROS1 including a novel variant of ROS1 fusions in lung adenocarcinoma: a case report","volume":"9","author":"Cai","year":"2014","journal-title":"J Thorac Oncol"},{"key":"R92-20260724","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1158\/1078-0432.CCR-11-3351","article-title":"Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion","volume":"18","author":"Rimkunas","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R93-20260724","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1038\/s41598-023-31055-3","article-title":"Systematic review of NTRK 1\/2\/3 fusion prevalence pan-cancer and across solid tumours","volume":"13","author":"O\u2019Haire","year":"2023","journal-title":"Sci Rep"},{"key":"R94-20260724","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.3390\/cancers15112966","article-title":"NTRK gene fusions in non-small-cell lung cancer: real-world screening data of 1068 unselected patients","volume":"15","author":"Overbeck","year":"2023","journal-title":"Cancers"},{"key":"R95-20260724","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.cllc.2019.09.004","article-title":"Evidence of NTRK1 fusion as resistance mechanism to EGFR TKI in EGFR+ NSCLC: results from a large-scale survey of NTRK1 fusions in Chinese patients with lung cancer","volume":"21","author":"Xia","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"R96-20260724","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","article-title":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","volume":"371","author":"Shaw","year":"2014","journal-title":"N Engl J Med"},{"key":"R97-20260724","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/annonc\/mdz131","article-title":"Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001","volume":"30","author":"Shaw","year":"2019","journal-title":"Ann Oncol"},{"key":"R98-20260724","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1470-2045(19)30690-4","article-title":"Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials","volume":"21","author":"Drilon","year":"2020","journal-title":"Lancet Oncol"},{"key":"R99-20260724","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1200\/JCO.20.03025","article-title":"Updated integrated analysis of the efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion\u2013positive non\u2013small-cell lung cancer","volume":"39","author":"Dziadziuszko","year":"2021","journal-title":"J Clin Oncol"},{"key":"R100-20260724","first-page":"100332","article-title":"Long-term efficacy and safety of entrectinib in ROS1 fusion\u2013positive NSCLC","volume":"3","author":"Drilon","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"R101-20260724","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1038\/s41591-024-03008-4","article-title":"Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2\/3 BFAST trial","volume":"30","author":"Peters","year":"2024","journal-title":"Nat Med"},{"key":"R102-20260724","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa2302299","article-title":"Repotrectinib in ROS1 fusion\u2013positive non\u2013small-cell lung cancer","volume":"390","author":"Drilon","year":"2024","journal-title":"N Engl J Med"},{"key":"R103-20260724","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41591-025-04079-7","article-title":"Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1\/2 trial","volume":"32","author":"Besse","year":"2026","journal-title":"Nat Med"},{"key":"R104-20260724","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1200\/JCO-25-00275","article-title":"Taletrectinib in ROS1+ non\u2013small cell lung cancer: TRUST","volume":"43","author":"P\u00e9rol","year":"2025","journal-title":"J Clin Oncol"},{"key":"R105-20260724","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"R106-20260724","doi-asserted-by":"crossref","first-page":"107442","DOI":"10.1016\/j.lungcan.2023.107442","article-title":"Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer","volume":"188","author":"Cho","year":"2024","journal-title":"Lung Cancer"},{"key":"R107-20260724","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion\u2013positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"R108-20260724","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol"},{"key":"R109-20260724","doi-asserted-by":"crossref","first-page":"105110","DOI":"10.1016\/j.esmoop.2025.105110","article-title":"Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer","volume":"10","author":"Hong","year":"2025","journal-title":"ESMO Open"},{"key":"R110-20260724","doi-asserted-by":"crossref","first-page":"e2100418","DOI":"10.1200\/PO.21.00418","article-title":"Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase fusion\u2013positive lung cancers","volume":"6","author":"Drilon","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"R111-20260724","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","article-title":"Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1)","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov"},{"key":"R112-20260724","doi-asserted-by":"crossref","first-page":"ix25","DOI":"10.1093\/annonc\/mdz420.004","article-title":"Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001","volume":"30","author":"Rolfo","year":"2019","journal-title":"Ann Oncol"},{"key":"R113-20260724","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/neuonc\/noaa052","article-title":"Entrectinib, a TRK\/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein","volume":"22","author":"Fischer","year":"2020","journal-title":"Neuro Oncol"},{"key":"R114-20260724","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.annonc.2020.05.006","article-title":"Characterization of on-target adverse events caused by TRK inhibitor therapy","volume":"31","author":"Liu","year":"2020","journal-title":"Ann Oncol"},{"key":"R115-20260724","doi-asserted-by":"crossref","first-page":"S787","DOI":"10.1016\/j.annonc.2023.09.2405","article-title":"1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: update from the phase I\/II TRIDENT-1 trial","volume":"34","author":"Solomon","year":"2023","journal-title":"Ann Oncol"},{"key":"R116-20260724","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S1470-2045(19)30655-2","article-title":"Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial","volume":"20","author":"Shaw","year":"2019","journal-title":"Lancet Oncol"},{"key":"R117-20260724","doi-asserted-by":"crossref","first-page":"100418","DOI":"10.1016\/j.esmoop.2022.100418","article-title":"Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study","volume":"7","author":"Girard","year":"2022","journal-title":"ESMO Open"},{"key":"R118-20260724","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1001\/jamaoncol.2025.5097","article-title":"Lorlatinib in tyrosine kinase inhibitor-naive advanced ROS1-positive non-small cell lung cancer: a phase 2 nonrandomized clinical trial","volume":"12","author":"Ahn","year":"2026","journal-title":"JAMA Oncol"},{"key":"R119-20260724","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41698-022-00264-w","article-title":"Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements","volume":"6","author":"Zhang","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"R120-20260724","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/clinchem\/hvae008","article-title":"Mechanisms of resistance to tyrosine kinase inhibitors in ROS1 fusion-positive nonsmall cell lung cancer","volume":"70","author":"Zhao","year":"2024","journal-title":"Clin Chem"},{"key":"R121-20260724","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jmoldx.2023.03.011","article-title":"RNA sequencing identifies novel NRG1 fusions in solid tumors that lack co-occurring oncogenic drivers","volume":"25","author":"Severson","year":"2023","journal-title":"J Mol Diagn"},{"key":"R122-20260724","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41698-025-01044-y","article-title":"Comprehensive identification of NRG1 fusions in 25,203 patients with solid tumors","volume":"9","author":"Xiang","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"R123-20260724","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1158\/1078-0432.CCR-14-0854","article-title":"Molecular pathways: targeting NRG1 fusions in lung cancer","volume":"21","author":"Fernandez-Cuesta","year":"2015","journal-title":"Clin Cancer Res"},{"key":"R124-20260724","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa2405008","article-title":"Efficacy of zenocutuzumab in NRG1 fusion\u2013positive cancer","volume":"392","author":"Schram","year":"2025","journal-title":"N Engl J Med"},{"key":"R125-20260724","doi-asserted-by":"crossref","first-page":"e2500221","DOI":"10.1200\/PO-25-00221","article-title":"CRESTONE: a phase II study of the efficacy and safety of the HER3 monoclonal antibody, seribantumab, in solid tumors with neuregulin-1 (NRG1) fusions","volume":"9","author":"Patil","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"R126-20260724","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00172","article-title":"BRAF in lung cancers: analysis of patient cases reveals recurrent BRAF mutations, fusions, kinase duplications, and concurrent alterations","volume":"2","author":"Sheikine","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"R127-20260724","doi-asserted-by":"crossref","first-page":"e878","DOI":"10.1016\/j.cllc.2021.05.003","article-title":"Lung adenocarcinoma with primary LIMD1-BRAF fusion treated with MEK inhibitor: a case report","volume":"22","author":"Wang","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"R128-20260724","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41586-021-04135-5","article-title":"The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer","volume":"600","author":"Izumi","year":"2021","journal-title":"Nature"},{"key":"R129-20260724","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1158\/1078-0432.CCR-21-4291","article-title":"RASGRF1 fusions activate oncogenic RAS signaling and confer sensitivity to MEK inhibition","volume":"28","author":"Hunihan","year":"2022","journal-title":"Clin Cancer Res"},{"key":"R130-20260724","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41698-025-01017-1","article-title":"Genetic and oncogenic features of RASGRF fusions","volume":"9","author":"Das","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"R131-20260724","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1158\/1078-0432.CCR-20-0397","article-title":"Identification of a RAS-activating TMEM87A-RASGRF1 fusion in an exceptional responder to sunitinib with non-small cell lung cancer","volume":"26","author":"Cooper","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R132-20260724","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1111\/cas.70142","article-title":"Discovery of novel RASGRF2 fusions as a therapeutic target in lung adenocarcinoma of never or light smokers","volume":"116","author":"Terashima","year":"2025","journal-title":"Cancer Sci"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000837","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T20:00:46Z","timestamp":1784923246000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":129,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000837","relation":{},"ISSN":["1540-336X"],"issn-type":[{"value":"1540-336X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2026-01-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}